Related Experiment Video
Updated: Aug 11, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat
The American Journal of Pathology
|October 1, 1985
Summary
Mitomycin directly causes kidney damage resembling human hemolytic uremic syndrome (HUS). This study provides a new model for HUS, clarifying its pathogenesis in cancer patients treated with mitomycin.
Area of Science:
- Nephrology
- Oncology
- Toxicology
Background:
- Hemolytic uremic syndrome (HUS) is a serious complication in cancer patients treated with mitomycin.
- The exact cause of mitomycin-induced HUS is not fully understood, with existing evidence being inconclusive.
Purpose of the Study:
- To investigate whether mitomycin can directly cause renal damage.
- To establish a potential animal model for studying mitomycin-induced HUS.
Main Methods:
- Lewis rats underwent perfusion of their left kidneys with varying doses of mitomycin.
- Control rats received saline perfusion only.
- Renal tissues were analyzed at intervals from 1 hour to 1 month post-perfusion.
Main Results:
- 29 out of 31 rats developed renal disease after mitomycin perfusion.
- Severe cortical infarction occurred in 9 rats receiving higher mitomycin doses (1000-4000 micrograms).
- Lesions mimicking human HUS were observed in 20 rats treated with lower mitomycin doses (60-500 micrograms), characterized by glomerular endothelial damage, platelet aggregation, and microangiopathy.
Conclusions:
- Mitomycin directly induces renal lesions that are indistinguishable from human HUS.
- This finding suggests a mechanism for renal injury observed in cancer patients treated with mitomycin.
- The study successfully established a novel rat model for HUS, aiding further research into its pathogenesis and treatment.
